The US Food and Drug Administration’s door is open to drug developers interested in integrating real-world data elements into randomized trials, but some regulatory skepticism about the reliability and utility of such data may linger behind that door.
At a recent Duke-Margolis Center for Health Policy meeting on leveraging randomized clinical trials to generate real-world evidence for regulatory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?